ArticleOncotarget2015

The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.

Yunyan Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.